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Abstract: 
The time in a woman's life when menstrual periods permanently stop; it is also called the "change of life."  
Menopause is defined as the time when there has been no menstrual periods for 12 consecutive months and no other 
biological or physiological cause can be identified. It is the end of fertility, the end of the childbearing years. (A 
woman may still, however, be able to become pregnant unless 12 consecutive months have passed without a period.) 
The last several weeks, this blog has discussed hormones during the reproductive cycle  as well as neuro-endo 
connections (e.g.  serotonin, estradiol, dopamine, progesterone).  Around age 38 the ovarian reserve declines 
rapidly significantly decreasing fertility.  At this point, there are far fewer follicles that can be recruited and, as a 
result, less egg maturation and release.  This ovarian depletion results in hormonal fluctuation.  All of this 
eventually leads up to a woman’s final menstrual period, which is on average around age 51. 
The first hormone to begin decreasing during perimenopause is progesterone.  As the number of follicles decreases, 
ovulation and the resulting corpus luteum formulation occurs less frequently. This significantly decreases the 
amount of progesterone produced. As progesterone levels begin to fall, gonadotropin releasing hormone (GnRH) 
increases, and as a result, follicle stimulating hormone (FSH) increases in an attempt to recruit a follicle. At the 
onset of menopause, when ovarian reserve is almost completely diminished, estradiol levels decrease dramatically 
and estrogen becomes the most abundant type of estrogen in the body.  
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INTRODUCTION: 
There are several points during the female life cycle 
when a woman's physiological rhythm changes. The 
female hormone estrogen has a great deal to do with 
the physical changes that occur at these points the 
onset of menstruation, pregnancy, childbirth and 
menopause. Hormones secreted by the ovaries bring 
about the changes in the female body that come with 
puberty marked by the beginning of the menstrual 
cycle, and then sexual maturity, when a woman is 
able to get pregnant and give birth.[1] 
Specifically, the change in estrogen concentration in 
the blood is closely related to life cycle. After 
adolescence, the concentration peaks as the body 
reaches sexual maturity and then decreases 
significantly during menopause.[2]In late 
reproductive life, menopause occurs after 12 months 
of amenorrhea and represents the near complete 
cessation of ovarian hormone secretion. The median 
age at menopause is 51.4 [3]. The menopausal 
transition refers to the time in each woman’s 
reproductive life that precedes the final menstrual 
period and is associated with changes in bleeding 
pattern and hormone profiles. Underlying these 
changes in bleeding pattern and hormonal profiles is 
the depletion of ovarian follicles. On average, women 
spend 4 years in menopausal transition, but there is 
considerable variability in length of menopausal 
transition.[4] 
Efforts to study these endocrinologic changes help to 
elucidate the biology of late reproductive aging, 
specifically ovarian aging. Further, hormone 
biomarkers that can identify timing of stages of 
reproductive aging, including predicting the final 
menstrual period, would have extensive clinical 
application.[5] The purpose of this report is to review 
the literature on hormonal changes associated with 
the menopausal transition. 
Several hormones in the hypothalamic-pituitary-
ovarian axis are markers of ovarian aging, including 
FSH, estradiol, inhibin B and AMH. FSH is secreted 
by the anterior pituitary gonadtrophes and is 
regulated in part through negative feedback by 
inhibin B and estradiol, hence an “indirect 
measure”.[6] As inhibin B and estradiol vary through 
each menstrual cycle, FSH levels fluctuate 
accordingly. With ovarian aging, lower inhibin B also 
results in decreased negative feedback to the 
pituitary, resulting in increased FSH secretion and 
higher early follicular FSH.[7] 
Hormones are the messengers in the body that travel 
through the blood stream to start, stop, speed up or 
slow down your physical and chemical functions and 
processes across all body systems.[8] Your ovaries 
are the source of estrogen and progesterone, the two 
key hormones that control the reproductive system, 
including the menstrual cycle and fertility in women. 
You are born with all the eggs you will ever have. [9] 
The eggs are in the follicles, which are found in the 
ovaries. During menopause, the number of ovarian 
follicles declines and the ovaries become less 
responsive to the two other hormones involved in 
reproduction Luteinizing Hormone (LH) and Follicle-
Stimulating Hormone (FSH). As your ovaries age 
and release fewer hormones, FSH and LH can no 
longer perform their usual functions to regulate your 
estrogen, progesterone and testosterone.[10] 
MATERIALS AND METHODS: 
The method of determination of hormonal status 
including in the research we use method of 
Vidas(Immunoasaay fluorescent test) for 
determination of hormone levels. In this research are 
taking the work of total of 10 years from 2009-2019 
from Clinical Hospital in Skopje and Clinical 
Hospital in Tetovo, Republic of North Macedonia. 
The patients was taking for determination of 
hormonal status in different period of menopause. In 
total group of 410 patients separated in different age 
groups. The first age groups from 1-10 years total of 
20 patients, second age group from 11-20 years total 
of 20 patients, third age group from 21-30 years total 
of 20 patients, fourth age group from 31-40 total of 
150 patients, fifth age group from 41-50 years total of 
150 patients, sixth age group from 51-70 years total 
of 50 patients. 
We take samples of blood vein for analyzedthe type 
of hormones and blood is mostly taken from the 
cubic vein or any other available vein.At the 
beginning the arm is connected and then disinfected 
with the wad of alcohol the chosen vein and bristled 
with the needle thread. Depending on what tests are 
required for plasma serum or blood elements, we can 
detect corneal (dry) and anti-coagulant 
- For serum we need dried herbs 
- For plasma - anticoagulant tubes 
- For blood elements - anticoagulant tubes 
After the serum blood serum collection the centrifuge 
is centrifuged in the centrifuge rotations per minute 
lasts 5 to 10 minutes. While plasma and blood 
elements, respectively with anticoagulants, should be 
carefully mixed from one side to the other, so that the 
blood components are not hemolytic. 
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Figure.1. The procedure of drawing blood for analyseshttp://wwwdailymail.co.uk/neës/article-2783675/Meet-
college-dropout-self-billionaire-fear-needles-inspired-invent-neë-ëay-test-blood.html) 
RESULTS: 
In this research we have women in different periods 
examined and determinate the level of hormones in 
before and after menopause. In total group of 410 
patients separated in different age groups. The first 
age groups from 1-10 years totalof 20 patients, 
second age group from 11-20 years total of 20 
patients, third age group from 21-30 years total of 20 
patients, fourth age group from 31-40 total of 150 
patients, fifth age group from 41-50 years total of 150 
patients, sixth age group from 51-70 years total of 50 
patients. In this age groups was determinate the level 
of hormones such as estrogen, progesterone, LH, 
FSH and vitamin D. These hormones havea major 
indication in different periods of perimenopause, 
menopause and post menopause.  
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Table.1. Prevalence of progesterone, LH and FSH in different age groups  
Different age groups Progesterone ng/ml LH mlU/ml FSH mlU/ml 
First age group 1-11 
years 
0.2 ng/ml 1.5 mlU/ml 3.5 mlU/ml 
Second age group 11-20 
years 
1 ng/ml 11.6 mlU/ml 8.7 mlU/ml 
Third age group 21-30 
years 
0.98 ng/ml 12.3 mlU/ml 14.4 mlU/ml 
Fourth age group 31-40 
years 
23.2 ng/ml 38.7 mlU/ml 8.2 mlU/ml 
Fifth age group 41-50 
years 
1 ng/ml 11.9 mlU/ml 30.9 mlU/ml 
Sixth age group 51-70 
years 
0.5 ng/ml 39.8 mlU/ml 52.4 mlU/ml 
 
 
Graph.2. The prevalence of progesterone in women in different age groups 
 
Women in different periods and stages the level of progesterone can be changed in postmenopausal period. The 
highest level of progesterone hormone is in women during 31-40 years and the level of this hormone is decreased in 
age group 41-50 and from 51-70 years. 
 
0
5
10
15
20
25
First age
group  1-10
years
Second age
group 11-20
years
Third age
group 21-30
years
Fourth age
group 31-40
years
Fifth age
group 41-50
years
Sixth age
group 51-70
years
n
g/
m
l
Prevalence of progesterone in women in different age groups 
IAJPS 2019, 06 (04), 8373-8380                  AlbulenaBeadiniet al                     ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 8377 
 
 
Graph.3. Prevalence of hormones LH and FSH in women in different age groups  
The prevalence of hormones LH and FSH in women in different age groups in different periods of menopause. The 
fourth age group has the prevalence of having a highest level of hormones before their menopause period.  
 
Graph.4. Prevalence of vitamin D in women in different periods of menopause  
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From the results obtained in different periods in women heath, we see a decreased in vitamin D in the age group of 
41-50 years and 51-70 of vitamin D, which is also affected by hormonal changes with estrogen reduction and the 
appearance of other health problems osteoporosis and the metabolism of calcium and phosphorus. 
 
Table.2. Percentage of lifetime disorders in male and female 
 Lifetime disorders 
Disorder Women (%) Men (%) Odds ratio 
Depression 22.9 13.1 1.46 (1.41-1.51) 
Dysthymia 6.2 3.5 1.31 (1.25-1.38) 
Generalized anxiety 5.8 3.1 1.34 (1.27-1.42) 
Panic disorder 7.2 3.7 1.39 (1.32-1.47) 
Social phobia 5.8 4.3 1.16 (1.10 – 1.22) 
Specific phobia 12.4 6.2 1.47 (1.41 – 1.53) 
Alcohol dependence 8.0 17.4 0.63 (0.60-0.65) 
Nicotine dependence 15.6 20.0 0.84 ( 0.81- 0.87) 
Marijuana dependence 0.9 1.7 0.77 (0.71 – 0.83) 
Other drug 
dependence 
1.4 2.2 0.84 ( 0.79- 0.90) 
Antisocial personality 1.9 5.5 0.68 ( 0.59- 0.66) 
 
These interactions demonstrate that the nervous and 
endocrine systems are intricately coupled, and both 
are involved in almost every bodily function 
including cognition, mood, reproduction, sleep, and 
temperature regulation. The correct balance of 
neurotransmitters and hormones is critical to 
preventing symptoms, as well as supporting overall 
health. 
DISCUSSION AND CONCLUSION: 
From the results obtained in different periods in 
women heath, we see a decreased in vitamin D in the 
age group of 41-50 years and 51-70 of vitamin D, 
which is also affected by hormonal changes.Period-
menopausal in women  age groups according to 
results obtained starting from 38.5 years to 51.8 years 
and ends.Hormones are chemicals that are produced 
by glands in the endocrine system. Hormones travel 
through the bloodstream to the tissues and organs, 
delivering messages that tell the organs what to do 
and when to do it.Hormones are important for 
regulating most major bodily processes, so a 
hormonal imbalance can affect a wide range of 
bodily functions. Hormones help to regulate: 
- metabolism and appetite 
- heart rate 
- sleep cycles 
- reproductive cycles and sexual function 
- general growth and development 
- mood and stress levels 
- body temperature 
Men and women alike can be affected by imbalances 
in insulin, steroids, growth hormones, and adrenaline. 
Women may also experience imbalances in estrogen 
and progesterone levels, while men are more likely to 
experience imbalances in testosterone levels. 
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Figure.2.a) The human menstrual cycleb) The dynamics of 
perimenopause(https://neuroendoimmune.wordpress.com/2013/12/03/hormonal-changes-in-menopause-is-it-all-
downhill-from-here/) 
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